EU Approval Verdicts Near For A Bumper Crop Of New Drugs
Novartis, Arvelle, AstraZeneca and Incyte are among a raft of drug sponsors who should find out shortly whether the European Medicines Agency will vote in favor of approving their products for use in the EU.
You may also be interested in...
New products from Paion, Arvelle, Incyte and many others have been recommended for approval by the European Medicines Agency. Meanwhile, the agency has explained why the EU marketing authorization application for Dexamethasone Taw, for treating COVID-19 patients, was withdrawn.
Kesimpta could become the first and only self-administered, targeted B-cell therapy for patients in Europe with relapsing forms of multiple sclerosis.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.